Research advances in susceptibility genes of non-alcoholic fatty liver disease and its association with type 2 diabetes

DU Te; CHEN Jing; SHEN Xu

doi:10.11665/j.issn.1000-5048.20180504

Journal of China Pharmaceutical University > 2018 > 49(5): 537-544. > DOI: 10.11665/j.issn.1000-5048.20180504

DU Te, CHEN Jing, SHEN Xu. Research advances in susceptibility genes of non-alcoholic fatty liver disease and its association with type 2 diabetes[J]. Journal of China Pharmaceutical University, 2018, 49(5): 537-544. DOI: 10.11665/j.issn.1000-5048.20180504

Citation:

PDF (1053 KB)

Research advances in susceptibility genes of non-alcoholic fatty liver disease and its association with type 2 diabetes

DU Te^1,2,
CHEN Jing^1,2,
SHEN Xu³

More Information

Graphical Abstract

Abstract

Abstract

Nonalcoholic fatty liver disease(NAFLD)as the most common hepatic disease worldwide is affected not only by extrinsic factors, but also by genetic ones. Type 2 diabetes mellitus(T2DM), another chronic disease regulated by both environmental and genetic factors, is closely related to NAFLD in signal pathways and susceptibility genes. This review summarizes the susceptibility genes of NAFLD, especially points out their relevance to T2DM and suggests their related clinical applications, which provide further evidence for the exploration of the mechanisms of the two diseases with a new direction for their diagnosis and treatment.
- nonalcoholic fatty liver disease,
- type 2 diabetes mellitus,
- susceptibility genes,
- correlation

FullText(HTML)

References (68)

References

[1]	Benedict M, Zhang X. Non-alcoholic fatty liver disease: an expanded review[J].World J Hepatol,2017,9(16):715-732.
[2]	Araújo AR,Rosso N,Bedogni G,et al.Global epidemiology of non-alcoholic fatty liver disease/non-alcoholic steatohepatitis:what we need in the future[J].Liver Int,2018,38(S1):47-51.
[3]	Perumpail BJ,Khan MA,Yoo ER,et al.Clinical epidemiology and disease burden of nonalcoholic fatty liver disease[J].World J Gastroenterol,2017,23(47):8263-8276.
[4]	Ioannou GN.The role of cholesterol in the pathogenesis of NASH[J].Trends Endocrinol Metab,2016,27(2):84-95.
[5]	Tilg H.How to approach a patient with nonalcoholic fatty liver disease[J].Gastroenterology,2017,153(2):345-349.
[6]	Taylor R.Insulin resistance and type 2 diabetes[J].Diabetes,2012,61(4):778-779.
[7]	Portillo-Sanchez P,Bril F,Maximos M,et al.High prevalence of nonalcoholic fatty liver disease in patients with type 2 diabetes mellitus and normal plasma aminotransferase levels[J].J Clin Endocr Metab,2015,100(6):2231-2238.
[8]	Seko Y,Sumida Y,Tanaka S,et al.Insulin resistance increases the risk of incident type 2 diabetes mellitus in patients with non-alcoholic fatty liver disease[J].Hepatol Res,2018,48(3):E42-E51.
[9]	Van Rooyen DM,Larter CZ,Haigh WG,et al.Hepatic free cholesterol accumulates in obese,diabetic mice and causes nonalcoholic steatohepatitis[J].Gastroenterology,2011,141(4):1393-1403.
[10]	Caligiuri A,Gentilini A,Marra F.Molecular pathogenesis of NASH[J].Int J Mol Sci,2016,17(9):1575.
[11]	Buzzetti E,Pinzani M,Tsochatzis EA.The multiple-hit pathogenesis of non-alcoholic fatty liver disease(NAFLD)[J].Metabolism,2016,65(8):1038-1048.
[12]	Loomba R,Schork N,Chen CH,et al.Heritability of hepatic fibrosis and steatosis based on a prospective twin study[J].Gastroenterology,2015,149(7):1784-1793.
[13]	Petersen KF,Dufour S,Feng J,et al.Increased prevalence of insulin resistance and nonalcoholic fatty liver disease in Asian-Indian men[J].Proc Natl Acad Sci U S A,2006,103(48):18273-18277.
[14]	Zhang Q,Wong C KH,Kung K,et al.Development and validation study of a non-alcoholic fatty liver disease risk scoring model among adults in China[J].Fam Pract,2017,34(6):667-672.
[15]	Browning JD, Szczepaniak LS, Dobbins R, et al. Prevalence of hepatic steatosis in an urban population in the United States:impact of ethnicity[J].Hepatology,2004,40(6):1387-1395.
[16]	Curti MLR, Jacob P, Borges MC, et al. Studies of gene variants related to inflammation,oxidative stress,dyslipidemia,and obesity:implications for a nutrigenetic approach[J].J Obes,2011,2011:497401.doi: 10.1155/2011/497401.
[17]	Kumari M,Schoiswohl G,Chitraju C,et al.Adiponutrin functions as a nutritionally regulated lysophosphatidic acid acyltransferase[J].Cell Metab,2012,15(5):691-702.
[18]	Ruhanen H,Perttilä J,Höttä-Vuori M,et al.PNPLA3 mediates hepatocyte triacylglycerol remodelling[J].J Lipid Res,2014,55(4):739-746.
[19]	Chen W,Chang B,Li L,et al.Patatin-like phospholipase domain-containing 3/adiponutrin deficiency in mice is not associated with fatty liver disease[J].Hepatology,2010,52(3):1134-1142.
[20]	Romeo S,Kozlitina J,Xing C,et al.Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease[J].Nat Genet,2008,40(12):1461-1465.
[21]	He S,McPhaul C,Li JZ,et al.A sequence variation(I148M)in PNPLA3 associated with nonalcoholic fatty liver disease disrupts triglyceride hydrolysis[J].J Biol Chem,2010,285(9):6706-6715.
[22]	Pingitore P,Pirazzi C,Mancina RM,et al.Recombinant PNPLA3 protein shows triglyceride hydrolase activity and its I148M mutation results in loss of function[J].Biochim Biophys Acta,2014,1841(4):574-580.
[23]	Bruschi FV,Claudel T,Tardelli M,et al.The PNPLA3 I148M variant modulates the fibrogenic phenotype of human hepatic stellate cells[J].Hepatology,2017,65(6):1875-1890.
[24]	Donati B,Motta BM,Pingitore P,et al.The rs2294918 E434K variant modulates patatin-like phospholipase domain-containing 3 expression and liver damage[J].Hepatology,2016,63(3):787-798.
[25]	Buch S,Stickel F,Tréo E,et al.A genome-wide association study confirms PNPLA3 and identifies TM6SF2 and MBOAT7 as risk loci for alcohol-related cirrhosis[J].Nat Genet,2015,47(12):1443-1448.
[26]	Viitasalo A,Eloranta AM,Atalay M,et al.Association of MBOAT7 gene variant with plasma ALT levels in children:the PANIC study[J].Pediatr Res,2016,80(5):651-655.
[27]	Mancina RM,Dongiovanni P,Petta S,et al.The MBOAT7-TMC4 variant rs641738 increases risk of nonalcoholic fatty liver disease in individuals of European descent[J].Gastroenterology,2016,150(5):1219-1230.
[28]	Luukkonen PK,Zhou Y,Hyöyläinen T,et al.The MBOAT7 variant rs641738 alters hepatic phosphatidylinositols and increases severity of non-alcoholic fatty liver disease in humans[J].J Hepatol,2016,65(6):1263-1265.
[29]	Loomba R,Quehenberger O,Armando A,et al.Polyunsaturated fatty acid metabolites as novel lipidomic biomarkers for noninvasive diagnosis of nonalcoholic steatohepatitis[J].J Lipid Res,2015,56(1):185-192.
[30]	Umano GR,Caprio S,Di Sessa A,et al.The rs626283 variant in the MBOAT7 gene is associated with insulin resistance and fatty liver in caucasian obese youth[J].Am J Gastroenterol,2018,113(3):376-383.
[31]	Kanuri G,Bergheim I.In vitro and in vivo models of non-alcoholic fatty liver disease(NAFLD)[J].Int J Mol Sci,2013,14(6):11963-11980.
[32]	Mota M,Banini BA,Cazanave SC,et al.Molecular mechanisms of lipotoxicity and glucotoxicity in nonalcoholic fatty liver disease[J].Metabolism,2016,65(8):1049-1061.
[33]	Nakayama H,Otabe S,Ueno T,et al.Transgenic mice expressing nuclear sterol regulatory element-binding protein 1c in adipose tissue exhibit liver histology similar to nonalcoholic steatohepatitis[J].Metabolism,2007,56(4):470-475.
[34]	Kobayashi M,Gouda K,Chisaki I,et al.Regulation of multidrug resistance protein 2(MRP2,ABCC2)expression by statins:involvement of SREBP-mediated gene regulation[J].Int J Pharmaceut,2013,452(1/2):36-41.
[35]	Araki E,Yamashita S,Arai H,et al.Effects of pemafibrate,a novel selective PPARα modulator,on lipid and glucose metabolism in patients with type 2 diabetes and hypertriglyceridemia:a randomized,double-blind,placebo-controlled,phase 3 trial[J].Diabetes Care,2018,41(3):538-546.
[36]	Pawlak M,Lefebvre P,Staels B.Molecular mechanism of PPARα action and its impact on lipid metabolism,inflammation and fibrosis in non-alcoholic fatty liver disease[J].J Hepatol,2015,62(3):720-733.
[37]	Eliades M,Spyrou E.Vitamin D:a new player in non-alcoholic fatty liver disease[J]?World J Gastroenterol,2015,21(6):1718-1727.
[38]	Mitri J,Pittas AG.Vitamin D and diabetes[J].Endocrinol Metab Clin North Am,2014,43(1):205-232.
[39]	Adams LA,White SW,Marsh JA,et al.Association between liver-specific gene polymorphisms and their expression levels with nonalcoholic fatty liver disease[J].Hepatology,2013,57(2):590-600.
[40]	Berridge MJ.Vitamin D deficiency and diabetes[J].Biochem J,2017,474(8):1321-1332.
[41]	Talaei A,Mohamadi M,Adgi Z.The effect of vitamin D on insulin resistance in patients with type 2 diabetes[J].Diabetol Metab Syndr,2013,5(1):8.
[42]	Rahman MM,Hosen MB,Faruk MO,et al.Association of vitamin D and vitamin D binding protein(DBP)gene polymorphism with susceptibility of type 2 diabetes mellitus in Bangladesh[J].Gene,2017,636:42-47.
[43]	Larsson M,Vorrsjö E,Talmud P,et al.Apolipoproteins CI and C-III inhibit lipoprotein lipase activity by displacement of the enzyme from lipid droplets[J].J Biol Chem,2013,288(47):33997-34008.
[44]	Miller M,Rhyne J,Chen H,et al.APOC3 promoter polymorphisms C-482T and T-455C are associated with the metabolic syndrome1[J].Arch Med Res,2007,38(4):444-451.
[45]	Petersen KF, Dufour S, Hariri A, et al. Apolipoprotein C3 gene variants in nonalcoholic fatty liver disease[J].N Engl J Med,2010,362(12):1082-1089.
[46]	Raposo HF,Paiva AA,Kato LS,et al.Apolipoprotein CIII overexpression exacerbates diet-induced obesity due to adipose tissue higher exogenous lipid uptake and retention and lower lipolysis rates[J].Nutr Metab,2015,12(1):61.
[47]	Zhu Y,Xu G,Patel A,et al.Cloning,expression,and initial characterization of a novel cytokine-like gene family[J].Genomics,2002,80(2):144-150.
[48]	Wang C,Chi Y,Li J,et al.FAM3A activates PI3K p110α/Akt signaling to ameliorate hepatic gluconeogenesis and lipogenesis[J].Hepatology,2014,59(5):1779-1790.
[49]	Cao X,Yang C,Lai F,et al.Elevated circulating level of a cytokine,pancreatic-derived factor,is associated with metabolic syndrome components in a Chinese population[J].J Diabetes Invest,2016,7(4):581-586.
[50]	MarElia CB,Kuehl MN,Shemwell TA,et al.Circulating PANDER concentration is associated with increased HbA1c and fasting blood glucose in type 2 diabetic subjects[J].J Clin Transl Endocrinol,2018,11:26-30.
[51]	Chen Z,Ding L,Yang W,et al.Hepatic activation of the FAM3C-HSF1-CaM pathway attenuates hyperglycemia of obese diabetic mice[J].Diabetes,2017,66(5):1185-1197.
[52]	Chen Z,Wang J,Yang W,et al.FAM3C activates HSF1 to suppress hepatic gluconeogenesis and attenuate hyperglycemia of type 1 diabetic mice[J].Oncotarget,2017,8(62):106038-106049.
[53]	Procopet B,Berzigotti A.Diagnosis of cirrhosis and portal hypertension:imaging,non-invasive markers of fibrosis and liver biopsy[J].Gastroenterol Rep,2017,5(2):79-89.
[54]	Kalhan SC,Guo L,Edmison J,et al.Plasma metabolomic profile in nonalcoholic fatty liver disease[J].Metabolism,2011,60(3):404-413.
[55]	Cernea S,Cahn A,Raz I.Pharmacological management of nonalcoholic fatty liver disease in type 2 diabetes[J].Exp Rev Clin Pharmacol,2017,10(5):535-547.
[56]	Liu YL,Reeves HL,Burt AD,et al.TM6SF2 rs58542926 influences hepatic fibrosis progression in patients with non-alcoholic fatty liver disease[J].Nat Commun,2014,5(4):4309.
[57]	Chalasani N,Guo X,Loomba R,et al.Genome-wide association study identifies variants associated with histologic features of nonalcoholic fatty liver disease[J].Gastroenterology,2010,139(5):1567-1576.
[58]	Santoro N,Zhang CK,Zhao H,et al.Variant in the glucokinase regulatory protein(GCKR)gene is associated with fatty liver in obese children and adolescents[J].Hepatology,2012,55(3):781-789.
[59]	Zain SM,Mohamed Z,Mohamed R.A common variant in the glucokinase regulatory gene rs780094 and risk of nonalcoholic fatty liver disease:a meta-analysis[J].J Gastroen Hepatol,2015,30(1):21-27.
[60]	Bauer RC,Yenilmez BO,Rader DJ.Tribbles-1:a novel regulator of hepatic lipid metabolism in humans[J].Biochem Soc T,2015,43(5):1079-1084.
[61]	Miele L,Beale G,Patman G,et al.The Kruppel-like factor 6 genotype is associated with fibrosis in nonalcoholic fatty liver disease[J].Gastroenterology,2008,135(1):282-291.
[62]	Tan HL,Mohamed R,Mohamed Z,et al.Phosphatidylethanolamine N-methyltransferase gene rs7946 polymorphism plays a role in risk of nonalcoholic fatty liver disease:evidence from meta-analysis[J].Pharmacogenet Genomics,2016,26(2):88-95.
[63]	Gorden A,Yang R,Yerges-Armstrong LM,et al.Genetic variation at NCAN locus is associated with inflammation and fibrosis in non-alcoholic fatty liver disease in morbid obesity[J].Hum Hered,2013,75(1):34-43.
[64]	Gouda W,Ashour E,Shaker Y,et al.MTP genetic variants associated with non-alcoholic fatty liver in metabolic syndrome patients[J].Genes Diseases,2017,4(4):222-228.
[65]	Zain SM,Mohamed Z,Mahadeva S,et al.Impact of leptin receptor gene variants on risk of non-alcoholic fatty liver disease and its interaction with adiponutrin gene[J].J Gastroen Hepatol,2013,28(5):873-879.
[66]	Al-Serri A,Anstee QM,Valenti L,et al.The SOD2 C47T polymorphism influences NAFLD fibrosis severity:evidence from case-control and intra-familial allele association studies[J].J Hepatol,2012,56(2):448-454.
[67]	Tian C,Fang S,Du X,et al.Association of the C47T polymorphism in SOD2 with diabetes mellitus and diabetic microvascular complications:a meta-analysis[J].Diabetologia,2011,54(4):803-811.
[68]	Gandotra S,Le Dour C,Bottomley W,et al.Perilipin deficiency and autosomal dominant partial lipodystrophy[J].N Engl J Med,2011,364(8):740-748.

Cited By

Get Citation

PDF

XML

Article views (591) PDF downloads (1142)

Turn off MathJax

Article Contents

Abstract

References

Research advances in susceptibility genes of non-alcoholic fatty liver disease and its association with type 2 diabetes

Abstract

References

Catalog

Export File

Citation

Format

Content